60 degrees pharmaceuticals suspends phase iib study of tafenoquine for covid-19, pivots to refocus on commercialization of treatments for malaria and tick-borne diseases

Fda advice to company suggested execution of aclr8-lr, a placebo-controlled phase iib study of tafenoquine in covid-19 patients, may not be feasible in the u.s. company will therefore focus efforts on further commercialization related to arakoda® (tafenoquine) for prophylaxis of malaria, and prepare for a phase iia study of tafenoquine in hospitalized babesiosis patients company is preparing for submission of a pre-ind meeting request with fda for babesiosis in the current fourth quarter of 2023, and plans to appoint a chief commercial officer to lead arakoda commercialization washington, oct. 12, 2023 (globe newswire) -- 60 degrees pharmaceuticals, inc. (nasdaq: sxtp; sxtpw) (“60p” or the “company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that its subsidiary, 60p australia pty ltd, will not re-submit its investigational new drug application (“ind”) for aclr8-lr, a phase iib study of tafenoquine compared to placebo in patients with mild to moderate covid-19 disease and low risk of disease progression. tafenoquine is the active molecule in arakoda ® , the company's u.s. food and drug administration (fda)-approved regimen for malaria prevention.
SXTP Ratings Summary
SXTP Quant Ranking